Amgen jumps after teasing weight-loss drug data, rival stocks fall

By Manas Mishra and Christy Santhosh (Reuters) -Amgen shares headed for their best session since 2009 on Friday after the U.S. drugmaker hinted at encouraging interim trial data on its experimental obesity drug, denting rival stocks but leaving analysts frustrated with a lack of details. Weight-loss drugmaker Eli Lilly’s shares fell 1.6% while Novo Nordisk’s…

Read More

CBRE Group’s first-quarter profit beats on leasing demand

(Reuters) – Real estate services provider CBRE Group’s first-quarter profit beat analysts’ estimates on Friday, helped by higher leasing demand at a time when commercial property sales remain under pressure from elevated interest rates. “Leasing outperformed expectations, driven by office leasing growth globally,” CBRE CEO Bob Sulentic said. The company’s global leasing revenue rose 4%,…

Read More

Rivian receives $827 million in incentives to expand Illinois facility, shares jump

(Reuters) -Rivian Automotive said on Thursday it has received $827 million in an incentive package from the State of Illinois to expand operations at its Normal facility. The Irvine, California-based company’s shares rose nearly 10% in afternoon trade after having lost more than 60% of their value this year, as of Wednesday’s close. The Illinois…

Read More

Russia breached global chemical weapons ban in Ukraine war, US says

By Jonathan Landay and Daphne Psaledakis WASHINGTON (Reuters) -The United States on Wednesday accused Russia of violating the international chemical weapons ban by deploying the choking agent chloropicrin against Ukrainian troops and using riot control agents “as a method of warfare” in Ukraine. “The use of such chemicals is not an isolated incident and is…

Read More

Pfizer lifts profit forecast as CEO sees reason for optimism in 2024

By Bhanvi Satija and Patrick Wingrove (Reuters) -Pfizer lifted its annual earnings forecast on Wednesday and reported a first-quarter profit above Wall Street estimates, boosted by cost cutting efforts and stronger-than-expected sales of its COVID antiviral treatment. Sales of Padcev, a treatment for advanced bladder cancer Pfizer gained through its $43 billion deal for Seagen,…

Read More

Mastercard’s profit beats as consumer spending defies inflation worries

By Mehnaz Yasmin (Reuters) -Mastercard reported first-quarter profit that exceeded Wall Street expectations on Wednesday, on higher card spending by consumers despite rising borrowing costs and persistent inflation. Wage growth and a tight labor market have ensured job security for card users, allowing them to spend without restraint even as the Federal Reserve keeps monetary…

Read More